Abbott India Ltd

Unaudited results (Q1 Jun 2026)

• Board approves unaudited results for quarter ended 30 June 2026.
• Walker Chandiok & Co LLP issued limited review report; no material misstatement identified.

Financial results

• Unaudited Q1 2026 results approved; Limited Review Report by Walker Chandiok & Co LLP.

Chairman transition

• Munir Shaikh stepped down as Chairman; Sudarshan Jain appointed Chairman, effective August 13, 2026.

Auditor remarks

• Walker Chandiok & Co LLP reviewed results; no material misstatement identified; audit opinion not expressed.

Annual Report distribution

• Annual Report FY2025-26 emailed to shareholders with registered email addresses.
• Web-link provided for unregistered emails to access the Annual Report.
• Link also available on BSE and NSDL evoting portals.
• Regulation 36(1)(b) compliance under SEBI LODR referenced.

Overview

• Standalone reporting boundary includes Goa Plant and Mumbai, Chembur, Chennai, Hyderabad, Lucknow, Delhi offices.
• Main activity: Pharmaceuticals manufacturing, marketing, sale and distribution; 100% turnover from pharma.
• Reporting period: April 1, 2025 to March 31, 2026.

Key ESG Risks & Opportunities

• Opportunity: Innovating for access; Extensior semaglutide launched with Novo Nordisk at accessible price.
• Opportunity: Water stewardship with four guiding principles; Goa water recycling and STP in HQ.
• Opportunity: Circular packaging and 90% waste diversion; ZWL at Goa and BKC; solar at Goa.
• Opportunity: Science-based targets; 73% Scope 2 reduction since 2018 baseline; ISO 50001.
• Opportunity: Quality management and TPMs to sustain product safety and compliance.
• Opportunity: Talent diversity programs; BeStrong and disAbility Network; internship expansion.
• Social impact: PHC upgradation program; 209 PHCs upgraded; live liver/thyroid screenings and vaccinations.

Governance & Policy Highlights

• Highest ESG authority: Managing Director Kartik Rajendran; board-level sustainability committee.
• Policies: Global anti-corruption, Code of Business Conduct, supplier guidelines; board-approved and translated.
• Assurance: DNV India provided reasonable assurance for BRSR Core indicators.
• Material penalties: GST penalty of 2.40 crore; RBI compounding of 0.02 crore.
• NGRBC alignment: All principles covered with board approval and procedures in place.
• External policy reviews: Internal reviews; no external agency for policy evaluation.

Social Responsibility & Workforce

• Total employees: 3,467; 3,080 male, 387 female; 212 permanent workers, 70 others.
• Board gender: 3 of 9 women; KMP: 2 of 3 women.
• Return-to-work: 100% RTW; permanent retention 85.08%; female retention 73.33%.
• LTIFR: 2.56 for employees; workers LTIFR not reported; total injuries 22 (employees).
• Well-being: BeStrong program; 24/7 EAP; multiple employee networks and flex work options.
• CSR: PHC upgradation; 39 PHCs upgraded in FY25-26; 5,840 ASHAs trained; 4,250 health workers trained.

Environmental Performance

• Total energy 45,138.49 GJ; renewable share 39.73%; energy intensity 6.51 GJ/Cr INR.
• Scope 1 emissions 155.39 MT CO2e; Scope 2 emissions 5,144.13 MT CO2e.
• Goa solar PV 286 kWp; 378 MWh generated; CO2 reduction 279.58 MT.
• Water withdrawal 66,466.51 KL; consumption 65,602.43 KL; water intensity 9.47 KL/Cr INR.
• Total waste 662.86 MT; 311.92 MT recycled; 262.73 MT reused; 35.44 MT disposed.
• ISO 50001:2018, ZWL certification; 90% waste diversion target; EPR plan filed.

Stakeholder Engagement & Complaints

• Key groups: patients, healthcare professionals, employees, NGOs, communities, suppliers, government, shareholders.
• Channels: meetings, reports, emails, websites, and investor communications; formal and informal engagement.
• Customer complaints: 342 filed; 66 pending at year-end; products-related data privacy and cyber topics tracked.
• Investors: 51 complaints filed; 4 pending; POSH complaints 1 filed; no unresolved sexual harassment cases at year-end.
• Speak Up portal and 24/7 helpline used for grievance redressal.

Other Notable Metrics

• Inputs: 22.19% from MSMEs; 44.28% from India; 11.07% local inputs at Goa.
• RPTs: Purchases from related parties 12.43%; sales to related parties 1.25%.
• Product recalls: NIL; data breaches: none reported in FY2025-26.
• Cyber-security policy in place; policy available on Abbott site.
• Assurance: DNV independent assurance of BRSR Core; sites audited include BKC and Goa plant.

AGM Details

• 82nd AGM on 13 August 2026 at 10:00 a.m., via VC/OAVM.

Key Resolutions

• Adoption of Audited Financial Statements for year ended 31 March 2026.
• Declaration of final dividend ₹525 and special dividend ₹131 per share.
• Munir Shaikh retires by rotation; not re-appointed.
• Kaiyomarz Marfatia retires by rotation; re-appointed.
• Remuneration ratification for Kishore Bhatia & Associates Cost Auditors for 2026-27.

Dividend Details

• Record date for dividend: 24 July 2026.
• Dividend payment from 18 August 2026.

Director Changes

• Munir Shaikh retires by rotation; not re-appointed.
• Kaiyomarz Marfatia retires by rotation; re-appointed.

Auditor Appointments

• Cost Auditors Kishore Bhatia & Associates remuneration for 2026-27: ₹0.09 crores plus taxes.

Financials & dividends

• Revenue from operations: ₹6,929 Cr; up 8.1% YoY.
• EBITDA: ₹2,180 Cr; EBITDA margin 31.5%.
• Profit after tax: ₹1,552 Cr; PAT margin 22.4%.
• EPS: ₹730.36; basic and diluted.
• Dividend final ₹525 and special ₹131 per share; payout ~90% of PAT.
• Cash from operations: ₹1,319 Cr; year-end cash ₹442.3 Cr.
• Domestic revenue ₹6,764 Cr; export revenue ₹82 Cr.

Business performance by area

• Udiliv led hepatoprotective GI portfolio; revenue >₹700 Cr.
• GI portfolio grew double-digit; Digeraft and Digene Insta On The Go expanded.
• Ganaton crossed ₹100 Cr; Digene awareness reached 44 million.
• Thyronorm leads Metabolics; Extensior launched in GLP-1 segment.
• Vaccines strengthened adult immunization; Influvac ranked among top 50 brands.
• CNS growth led by Vertin; focus on vertigo diagnosis and guidelines.
• Arachitol Nano drove Multi-Specialty growth; D-STRONG Life expanded Vitamin D testing.
• New launches: Extensior, Ezybixy, Duphalac Rapid, Digene Insta On The Go, Combinorm Plus.

Growth strategy & outlook

• Focus on high-burden, underpenetrated therapies; balanced organic and partnership growth.
• Strengthen core brands; pursue selective partnerships and acquisitions.
• Leverage digital/analytical capabilities; expand access in Tier 2 and Tier 3 markets.
• Priorities: deepen scientific leadership, expand access, strengthen growth in chronic care, and manage productivity.

Governance & leadership changes

• Kartik Rajendran appointed MD for five years from 14 June 2025.
• Swati Dalal ceased MD role on 13 June 2025.
• James Wenner appointed Director from 23 Apr 2026; Neeraj Jain Independent from 25 Apr 2026.
• Darshan Gada appointed Additional Non-Executive Director from 18 Aug 2025; Vivek Mohan from 1 Jan 2026.
• Independent Directors affirmed independence; seven board meetings held during the year.

CSR & sustainability

• CSR spend ₹29.80 Cr; approved ₹31.89 Cr; ₹28.20 Cr cash and ₹1.57 Cr non-cash.
• PHCs upgraded: 209 across 12 states; 5,840 ASHAs and 4,250 health workers trained.
• Screening: ~4.5 lakh liver and ~9.5 lakh thyroid tests conducted.
• New launches: Extensior, Ezybixy, Duphalac Rapid; Extensior via Novo Nordisk.
• Renewables: Goa plant generated 378 MWh; 279.58 MT CO2 avoided.
• Goa plant ZWL; 66% non-hazardous waste repurposed; 34% recycled; 99.35% hazardous waste co-processed.
• STEM: 4,600 students; 14 STEM labs; 345 capacity-building workshops; 2,820 frontline workers trained.
• One Abbott Blood Donation Drive 2025: 1,143 units donated.

Audits, risk management & controls

• Statutory auditors: Walker Chandiok; Internal auditors: Deloitte; Secretarial: BNP & Associates.
• Auditors’ report: no adverse remarks; key audit matter: sales returns provision ₹207.53 Cr.
• RBI compounding: ₹0.02 Cr; RBI order; compounding resolved; foreign investment limit raised to 80%.
• Internal controls: adequate and operating effectively; no fraud reported.
• Note on accounting software: audit trail feature not enabled at database level.

Related party disclosures

• Ultimate holding company: Abbott Laboratories; remittance of dividend ₹509.16 Cr; RSU payments ₹13.44 Cr.
• Remittances to fellow subsidiaries; sales/purchases with Abbott group across multiple entities.
• Outstanding balances with fellow subsidiaries: trade payables ₹118.57 Cr; lease liabilities ₹124.89 Cr.
• Note 39 provides detailed related party transactions.

ESG & assurance

• BRSR Core assurance by DNV; scope FY2025-26; covers 9 ESG attributes.
• DNV VeriSustain methodology; independent assurance; site sampling per Annexure II.
• Assurance confirms KPI disclosures align with SEBI BRSR Core requirements.

Dematerialisation processing and listing status

• Processing of dematerialisation requests confirmed; dematerialised securities listed on the exchanges.
• Physical certificates for dematerialisation mutilated and cancelled; depository name substituted as registered owner within the prescribed timeline.